Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy

被引：0
|
作者：
Maria D Cao
Guro F Giskeødegård
Tone F Bathen
Beathe Sitter
Anna Bofin
Per E Lønning
Steinar Lundgren
Ingrid S Gribbestad
机构：
[1] Norwegian University of Science and Technology (NTNU),Department of Circulation and Medical Imaging
[2] St Olavs University Hospital,Department of Laboratory Medicine
[3] Children's and Women's Health,Department of Oncology
[4] NTNU,Section of Oncology
[5] Haukeland University Hospital,Department of Oncology
[6] Institute of medicine,Department of Cancer Research and Molecular Medicine
[7] University of Bergen,Department of Circulation and Medical Imaging, The Faculty of Medicine
[8] St. Olavs Hospital,undefined
[9] University Hospital of Trondheim,undefined
[10] NTNU,undefined
[11] NTNU,undefined
[12] MTFS,undefined
来源：
BMC Cancer | / 12卷
关键词：
Breast Cancer Survival; Metabolic Response; Partial Little Square Discriminant Analysis; Partial Little Square Discriminant Analysis Model; Glycine Level;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Prognostic value of metabolic response in breast cancer patients receiving neoadjuvant chemotherapy
    Cao, Maria D.
    Giskeodegard, Guro F.
    Bathen, Tone F.
    Sitter, Beathe
    Bofin, Anna
    Lonning, Per E.
    Lundgren, Steinar
    Gribbestad, Ingrid S.
    [J]. BMC CANCER, 2012, 12
  • [2] Predictive and prognostic value of EPIC1 in patients with breast cancer receiving neoadjuvant chemotherapy
    Xu, Yaqian
    Wang, Yan
    Yuan, Chenwei
    Sheng, Xiaonan
    Sha, Rui
    Dai, Huijuan
    Zhang, Shan
    Wang, Yaohui
    Lin, Yanping
    Zhou, Liheng
    Xu, Shuguang
    Zhang, Jie
    Yin, Wenjin
    Lu, Jinsong
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [3] Prognostic factors for response to neoadjuvant chemotherapy in patients with breast cancer
    Kang, S. Y.
    Jung, Y. S.
    Kim, K. S.
    [J]. BREAST, 2011, 20 : S48 - S48
  • [4] The response to neoadjuvant chemotherapy as a prognostic factor in breast cancer patients
    Ruiz, C
    Barros, A
    Motta, E
    Pinotti, J
    [J]. BREAST, 1997, 6 (05): : P949 - P949
  • [5] Pathological complete response in breast cancer patients receiving neoadjuvant chemotherapy
    Montemurro, Filippo
    Di Cosimo, Serena
    [J]. BREAST, 2014, 23 (05): : 690 - 691
  • [6] Plasma and tissue proteomic prognostic factors of response in primary breast cancer patients receiving neoadjuvant chemotherapy
    Bonneterre, J.
    Revillion, F.
    Desauw, C.
    Blot, E.
    Kramar, A.
    Fournier, C.
    Hornez, L.
    Peyrat, J. P.
    [J]. ONCOLOGY REPORTS, 2013, 29 (01) : 355 - 361
  • [7] Predictive and Prognostic Value of TRIM58 Protein Expression in Patients with Breast Cancer Receiving Neoadjuvant Chemotherapy
    Zheng, Yi-Zi
    Li, Jia-Ying
    Ning, Lv-Wen
    Xie, Ni
    [J]. BREAST CANCER-TARGETS AND THERAPY, 2022, 14 : 475 - 487
  • [8] Prognostic Value of Receptor Change After Neoadjuvant Chemotherapy in Breast Cancer Patients
    Ozdemir, Ozlem
    Zengel, Baha
    Cavdar, Demet Kocatepe
    Yilmaz, Cengiz
    Durusoy, Raika
    [J]. EUROPEAN JOURNAL OF BREAST HEALTH, 2022, 18 (02) : 167 - 171
  • [9] Prognostic Factors of Locally Advanced Breast Cancer Patients Receiving Neoadjuvant and Adjuvant Chemotherapy
    Akhsan, Alfiyannul
    Aryandono, Teguh
    [J]. ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2010, 11 (03) : 759 - 761
  • [10] Biodynamic response prediction in breast cancer patients receiving neoadjuvant chemotherapy.
    Morgan, Travis
    Whitacre, Eric
    Burak, William
    Manahan, Eric
    Goedde, Timothy
    Greenspan, Andrew
    Woods, John
    Nolte, David
    Turek, John
    Loesch, David M.
    An, Ran
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345